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Abstract
TRAIL-R2 (DR5) is a clinically-relevant therapeutic target and a key target for immune effector cells. Herein, we identify a
novel interaction between TRAIL-R2 and the Skp1-Cullin-1-F-box (SCF) Cullin-Ring E3 Ubiquitin Ligase complex
containing Skp2 (SCFSkp2). We find that SCFSkp2 can interact with both TRAIL-R2’s pre-ligand association complex
(PLAC) and ligand-activated death-inducing signalling complex (DISC). Moreover, Cullin-1 interacts with TRAIL-R2 in its
active NEDDylated form. Inhibiting Cullin-1’s DISC recruitment using the NEDDylation inhibitor MLN4924 (Pevonedistat)
or siRNA increased apoptosis induction in response to TRAIL. This correlated with enhanced levels of the caspase-8
regulator FLIP at the TRAIL-R2 DISC, particularly the long splice form, FLIP(L). We subsequently found that FLIP(L) (but
not FLIP(S), caspase-8, nor the other core DISC component FADD) interacts with Cullin-1 and Skp2. Importantly, this
interaction is enhanced when FLIP(L) is in its DISC-associated, C-terminally truncated p43-form. Prevention of FLIP(L)
processing to its p43-form stabilises the protein, suggesting that by enhancing its interaction with SCFSkp2, cleavage to the
p43-form is a critical step in FLIP(L) turnover. In support of this, we found that silencing any of the components of the
SCFSkp2 complex inhibits FLIP ubiquitination, while overexpressing Cullin-1/Skp2 enhances its ubiquitination in a
NEDDylation-dependent manner. DISC recruitment of TRAF2, previously identified as an E3 ligase for caspase-8 at the
DISC, was also enhanced when Cullin-1’s recruitment was inhibited, although its interaction with Cullin-1 was found to be
mediated indirectly via FLIP(L). Notably, the interaction of p43-FLIP(L) with Cullin-1 disrupts its ability to interact with
FADD, caspase-8 and TRAF2. Collectively, our results suggest that processing of FLIP(L) to p43-FLIP(L) at the TRAIL-R2
DISC enhances its interaction with co-localised SCFSkp2, leading to disruption of p43-FLIP(L)’s interactions with other
DISC components and promoting its ubiquitination and degradation, thereby modulating TRAIL-R2-mediated apoptosis.
Introduction
Apoptosis plays a key role in maintaining normal tissue
homeostasis and preventing disease [1]. Apoptosis is orche-
strated by a family of cysteine proteases, the caspases [2]. The
complex formed following activation of the TRAIL-R1/R2
(DR4/DR5) death receptors is called the death-inducing sig-
nalling complex (DISC), consisting of the receptors, the
adaptor molecule FADD, procaspase-8 and FLIP [3]. FADD
recruits procaspase-8 into this complex [4]. Procaspase-8
dimerization results in conformational changes in its catalytic
domains that are necessary for its activation [5]. Two main
splice forms of FLIP have been identified: a long form (FLIP
(L)) and a short form (FLIP(S)), both of which can be recruited
to the DISC and related complexes (such as TNFR1 Complex
II and the ripoptosome) where they form heterodimers with
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procaspase-8 and regulate its processing and activity [4].
Therefore, the relative amounts of FLIP(S) and FLIP(L)
recruited to the DISC is a key determinant of cell fate.
Although immune effector cells express TRAIL, rather than
being lost, TRAIL-R2 is commonly over-expressed on malig-
nant cells [6–8]. In pre-clinical studies, TRAIL was demon-
strated to activate apoptosis selectively in cancer cells
compared to normal cells [9, 10]. Thus, TRAIL receptors are
promising targets for selective targeting of tumor cells. Whilst
some promising activity was seen in early clinical trials of 1st
generation TRAIL-R-targeted therapeutics [11, 12], overall
single-agent activity was limited. Emerging 2nd generation
TRAIL-R2-selective agents are multivalent, exhibit potent pre-
clinical activity and have now reached early phase clinical
trials. It is therefore important to understand how apoptosis
signalling from this receptor is regulated, not only to under-
stand TRAIL-mediated anti-tumor immunity, but also to pre-
dict and enhance response to 2nd generation TRAIL-R2
agonists.
NEDD8 is a 9 kDa ubiquitin-like protein (UBL) [13, 14].
Just like the ubiquitination cascade, the NEDDylation cascade
relies on an E1/E2/E3 enzyme system; this results in the for-
mation of an isopeptide bond between the C-terminus of
NEDD8 (Gly76) and a substrate’s lysine residue. The most
researched NEDDylation substrates are the Cullin-Ring E3
Ligase (CRL) family of E3 ubiquitin ligases [15, 16]. CRLs are
multimeric ubiquitin E3 ligases made up of three components
(Fig. 1a): the Cullin, which acts as a scaffold; the C-terminal
RING finger domain-containing Rbx1/2 catalytic subunit; and
the N-terminal substrate-binding domain, which consists of an
adaptor (that binds the Cullin) and substrate receptor (that binds
the target protein). The activity of CRLs is critically dependent
on NEDDylation: when a CRL is NEDDylated, it is active.
The CRLs account for roughly 20% of all proteasomal
degradation within the cell [17, 18], and many CRL proteins,
especially the F-box family of proteins, have been linked to
tumorigenesis [19]. It has become increasingly apparent how
crucial ubiquitination is for Death Receptor signalling [20],
including the TRAIL-R2 DISC, at which caspase-8 activation
has been shown to be regulated by Cullin-3 [21].
In this study, we identify the Skp1-Cullin-1-F-box protein
containing Skp2 complex (SCFSkp2) as a TRAIL-R2-associated
complex that regulates apoptosis signalling from the DISC by
interacting with and modulating turnover of FLIP(L).
Results
The NEDDylation inhibitor MLN4924 enhances
rather than inhibits TRAIL-induced apoptosis
Cullin-3 has been reported to interact with the DISC, where
it promotes K63-linked ubiquitination of the p10-subunit of
caspase-8, which then results in recruitment of active
caspase-8 into ubiquitin-rich foci that in turn enhances its
enzymatic activity and apoptosis induction [21]. As inhi-
bition of NEDD8-activating E1 enzyme (NAE1) blocks
Cullin NEDDylation thereby rendering CRLs inactive
(Fig. 1a), it was surprising that MLN4924 (TAK4924/
Pevonedistat), a selective small-molecule inhibitor of the
NAE1 [22], significantly enhanced rather than inhibited
TRAIL-induced apoptosis in HCT116 colorectal cancer
(CRC) (Fig. 1b and Supplementary Fig. 1a), A549 non-
small cell lung cancer (NSCLC) and HT29 CRC (Supple-
mentary Fig. 1b) cell lines. Moreover, in HCT116 cells co-
treated with TRAIL and MLN4924 for 6 h, enhanced levels
of the active subunit of caspase-8 (p18) were detected by
Western blot, and this correlated with enhanced PARP
cleavage and caspase-8 activity (Fig. 1c, d). In addition, the
levels of p43-FLIP(L) and p43/41-caspase-8 were elevated
in MLN4924/TRAIL co-treated cells (Fig. 1c). Further-
more, the effects of MLN4924 on caspase-8 and FLIP(L)
processing were not due to downstream apoptosis signalling
as almost identical effects were observed in BAX-deficient
cells (Fig. 1c, d), although full processing of caspase-3
leading to PARP cleavage in this model was inhibited (this
was expected as HCT116 cells are “Type 2”, meaning they
require involvement of the mitochondrial apoptotic pathway
to amplify the apoptotic signal from the DISC [23]). These
effects were also maintained after 24 h, including main-
tenance of NEDDylation inhibition as indicated by the
absence of NEDDylated Cullin-1 (Supplementary Fig. 1c).
Identification of Cullin-1 as a novel TRAIL-R2 DISC-
interacting protein
Based on these results, we hypothesized that another
NEDDylation-dependent Cullin may modulate TRAIL-
induced apoptosis at the DISC. Using a DISC IP assay
for stimulating TRAIL-R2 DISC formation and then
assessing its components [24], we found that, in addition to
Cullin-3, Cullin-1 was also present (Fig. 1e and Supple-
mentary Fig. 1d). Moreover, Cullin-1 was primarily
recruited in its NEDDylated form, as pre-treatment with
MLN4924 almost completely abrogated its DISC recruit-
ment. A very small amount of non-NEDDylated Cullin-1
was still detected at the DISC in MLN4924-treated cells at 1
and 3 h. By comparison, Cullin-3 was detected equally in its
NEDDylated and non-NEDDylated forms at the DISC, and
was still present (predominantly in its non-NEDDylated
form) following MLN4924 pre treatment. Thus, it appears
that de-NEDDylated Cullin-1 is not retained at the DISC to
the same extent as de-NEDDylated Cullin-3. In addition,
NEDDylated Cullin-3 was almost completely lost; however,
a corresponding increase in non-NEDDylated Cullin-3 was
observed, suggesting that the total amount of Cullin-3 at the
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DISC is largely unaffected by NEDDylation status, whereas
this is crucial for Cullin-1 recruitment. The pre treatment
with MLN4924 also affected the core DISC components
FLIP(L) (detected as its caspase-8 processed form p43-FLIP
(L)) and caspase-8 (detected as its pro-form and partially
processed p41/43-forms), the levels of both of which were
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significantly enhanced at the 1 and 3 h timepoints (Fig. 1e).
FLIP(S) recruitment was also somewhat increased at these
timepoints. Although FADD levels decreased over time, its
levels were similar in control and MLN4924-treated sam-
ples within each timepoint. The levels of another DISC
component, TRAF2, which has been reported to be a
negative regulator of caspase-8 activity at the TRAIL-R2
DISC [25], were markedly enhanced by MLN4924
treatment.
Proteasome inhibitors have been reported to enhance
DISC-mediated caspase-8 activation by inhibiting TRAF2-
mediated ubiquitination of its large catalytic subunit [25].
We, therefore, compared the impact of MLN4924 and
MG132 on TRAIL-R2 DISC assembly (Fig. 1f and Sup-
plementary Fig. 1e). Treatment with both MLN4924 and
MG132 enhanced the levels of both FLIP(L) and TRAF2
detected at the TRAIL-R2 DISC. MG132 and to a lesser
extent MLN4924 also enhanced FLIP(S) levels at the DISC.
Another notable effect of MLN4924 was to reduce the
levels of poly-ubiquitinated caspase-8 detectable at the
DISC. This is consistent with inhibition of Cullin-3-
mediated caspase-8 ubiquitination; however, if Cullin-3-
mediated ubiquitination enhances caspase-8 activity as has
been reported [25], we would have expected to see a
decrease in TRAIL-induced caspase-8 activation and
apoptosis in MLN4924-treated cells rather than the
observed increases (Fig. 1b–d). Treatment with MLN4924
also decreased the levels of RIPK1 detected at the DISC, a
major substrate of the DISC-bound FLIP(L):caspase-8 het-
erodimer. In the presence of the pan-caspase inhibitor
zVAD-fmk, it was easier to visualise the effects of
MLN4924, with enhanced levels of p43-FLIP(L) and
TRAF2, decreased levels of poly-ubiquitinated caspase-8
and decreased levels of RIPK1 were, again, observed. Due
to its ability to partially inhibit DISC-bound caspase-8,
unprocessed FLIP(L) was detected in the presence of
zVAD-fmk, and both MLN4924 and MG132 enhanced the
levels of this form of FLIP(L) present in the complex.
The Skp1-Cullin-1-F-box protein containing Skp2
complex (SCFSkp2) is associated with TRAIL-R2
To further investigate the role of Cullin-1 at the TRAIL-R2
DISC, we assessed its recruitment in a panel of colorectal
cancer cell line models with differing degrees of TRAIL
sensitivity. Cullin-1 was detected at the TRAIL-R2 DISC in
TRAIL-sensitive HCT116 models and TRAIL-resistant
HT29 cells, but was barely detectable in RKO, LIM1215
and COLO205 DISC IPs (Fig. 2a). Moreover, Cullin-1’s
core binding partners Rbx1 and Skp1 were also detected in
the HCT116 and HT29 models. Previous studies have
linked resistance to TRAIL-induced apoptosis to Skp2[26],
an F-box protein that is a part of the substrate receptor for
the SCF CRL complex (Fig. 1a); therefore, we assessed
whether Skp2 also associated with the TRAIL-R2 DISC.
Skp2 was indeed detected, with higher levels at the TRAIL-
R2 DISCs formed in the p53 mutant HT29 model and an
isogenic p53 null HCT116 daughter cell line than in the p53
wild-type parental HCT116 model, an effect not attributable
to higher levels of expression of the complex’s components
(Supplementary Fig. 2a), suggesting a role for p53 in
complex formation. Very low, if any, SCFSkp2 complex
components could be detected in the DISCs formed by the
LIM1215 and COLO205 cells (Fig. 2a), although these
TRAIL-resistant models expressed low levels of the
SCFSkp2 complex (Supplementary Fig. 2a) and cell surface
TRAIL-R2 (as indicated by the amount of TRAIL-R2
immunoprecipitated). Although the TRAIL-resistant RKO
model expressed all the SCFSkp2 components to a similar
level as HCT116 and HT29 cell lines (Supplementary
Fig. 2a), very little SCFSkp2 was detected at the DISC
despite significant cell surface TRAIL-R2 expression
(Fig. 2a). The levels of caspase-8 and FLIP at the DISC
were also low at the RKO TRAIL-R2 DISC despite similar
levels of expression (Supplementary Fig. 2a) and similar
levels of FADD recruitment (Fig. 2a) to the other models.
Recruitment of Cullin-3 followed a similar pattern to
recruitment of Cullin-1.
Importantly, despite similar expression of all SCFSkp2
components (Supplementary Fig. 2b), none of the compo-
nents of the SCFSkp2 complex were detected in HCT116
cells in which TRAIL-R2 had been deleted (Fig. 2b), con-
firming the specificity of the interaction. However, in cells
lacking FADD, in which neither caspase-8 nor FLIP were
recruited, Cullin-1 and the rest of the complex were
detected at the DISC (Fig. 2b). Moreover, in HCT116 cells
lacking caspase-8, recruitment of the SCFSkp2 complex was
Fig. 1 The NEDDylation inhibitor MLN4924 enhances TRAIL-
induced apoptosis. a Schematic diagram of the Skp1-Cullin-1-F-box
protein (SCF) Cullin-RING Ligase (CRL) complex and its regulation
by NEDDylation. b High content microscopy analysis of cell death in
HCT116 cells pre-treated with MLN4924 (100 nM) for 1 h, before
treatment with rTRAIL for an additional 24 h. A student’s T test was
performed between DMSO and MLN4924-treated samples (Error
bars= SEM, ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05,
ns= p > 0.05). cWestern blot analyses and matched caspase-8 activity
assays (d) in HCT116 parental and Bax-deficient cells co-treated with
MLN4924 (100 nM) and rTRAIL (10 ng/mL) for 6 h. A two-way
ANOVA was performed between Ctrl vs rTRAIL and MLN4924 vs
Combo in each cell line (Error bars= SEM, ****p < 0.0001, ***p <
0.001, **p < 0.01, *p < 0.05, ns= p > 0.05). eWestern blot analyses of
TRAIL-R2 DISC IP in HCT116 BAX-null cells pre-treated with
MLN4924 (100 nM) for 1 h, prior to activation of the TRAIL-R2
receptor for the indicated times. f Western blot analysis of TRAIL-R2
DISC IP in HCT116 BAX-null cells treated for 1 h with MLN4924
(100 nM) or MG132 (10 µM) prior to activation of the TRAIL-R2
receptor for 1 h; cells were pre-treated with 20 µM zVAD-fmk pan-
caspase inhibitor for 2 h as indicated.
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Fig. 2 Identification of the SCFSkp2 complex as a novel TRAIL-R2
DISC-interacting protein. a Western blot analysis of TRAIL-R2
DISC IP (1 h) in a panel of colorectal cancer cell lines. b Western blot
analysis of TRAIL-R2 DISC IP (1 h) in parental and TRAIL-R2/
FADD/caspase-8 CRISPR knockout HCT116 cell lines. c Western
blot analysis of TRAIL-R2 DISC IP (1 h) in parental and FADD/
caspase-8 CRISPR knockout A549 cells; parental and caspase-8
CRISPR knockout HCT116 cells; parental and FLIP CRISPR
knockout HAP1 cells. d Timecourse Western blot analysis of TRAIL-
R2 DISC IP in HCT116 BAX-null cells.
2730 J. Z. Roberts et al.
actually enhanced; in these cells, FADD was recruited to the
DISC, but FLIP recruitment was impaired, consistent with
observations made by us and others [27, 28]. In the A549
NSCLC model, lack of caspase-8 and FADD both enhanced
Cullin-1 DISC recruitment (Fig. 2c and Supplementary
Fig. 2c). FLIP (CFLAR) deletion in the HAP1 CML-derived
cell line partially reduced Cullin-1 association with the
TRAIL-R2 DISC as well as markedly inhibiting processing
of procaspase-8 to its p41/43-forms.
In timecourse studies, components of the SCFSkp2 com-
plex (and TRAF2) were all found to be associated with the
unstimulated TRAIL-R2 (Fig. 2d; 0 min). Moreover, sti-
mulation of TRAIL-R2 caused an initial loss of the recep-
tor’s association with SCFSkp2, followed by re-association
with similar dynamics as TRAF2 and canonical DISC
proteins, FLIP, FADD and caspase-8 (Fig. 2d and Supple-
mentary Fig. 2d). Collectively, these results indicate that,
like TRAF2, the SCFSkp2 complex can associate with both
the TRAIL-R2 pre-ligand-association complex (PLAC) and
the ligand-activated TRAIL-R2 DISC. Furthermore, NED-
Dylated Cullin-1 was detected in membrane fractions,
which were also enriched in TRAIL-R2 and canonical
DISC and SCFSkp2 components (Supplementary Fig. 3a),
indicating that these proteins can co-locate. Collectively,
these results identify the SCFSkp2 complex as a novel
TRAIL-R2-associated complex.
Cullin-1 can regulate the composition and signalling
outcomes of the TRAIL-R2 DISC
As MLN4924 affects multiple substrates, not least Cullin-3,
we assessed to what extent its effects on TRAIL-R2 com-
position and signalling are Cullin-1-dependent using a
Cullin-1-directed siRNA pool (siCul1). At the DISC,
increases in p43-FLIP(L) and TRAF2 were observed in
siCul1-transfected cells (Fig. 3a and Supplementary
Fig. 3b). Similar effects were observed in the presence of
zVAD-fmk along with increases in (the now observable)
unprocessed FLIP(L) and a slight increase in FLIP(S).
siCul1 had less impact on poly-ubiquitinated caspase-8 than
MLN4924 (Fig. 3a), consistent with this effect of the
NEDDylation inhibitor being mediated via Cullin-3 as
previously reported [25], and its impact on RIPK1 levels
was small. Additionally, depleting had little effect on
Cullin-3 recruitment to the DISC (Supplementary Fig. 3c);
this suggests that Cullin-1 and Cullin-3 DISC recruitment
are not inter-dependent. Collectively, these results indicate
that the interaction of Cullin-1 with the TRAIL-R2 DISC
mainly affects the levels of FLIP(L) and TRAF2 associated
with the complex.
The impact of these changes on TRAIL-induced apop-
tosis was similar to those observed for MLN4924, with
increased levels of cleaved PARP and p18-caspase-8
(Fig. 3b) and significantly enhanced cell death induction
(Fig. 3c). Similar results were obtained using Skp2-directed
siRNAs (siSkp2) (Supplementary Fig. 3d) and in other
models (A549 and HT29) in which Cullin-1 was detected at
the DISC (Fig. 3d).
Analogous to the effects of CRISPR-mediated deletion
of FLIP in HAP1 cells (Fig. 2c), siRNA-mediated down-
regulation of FLIP(L) in HCT116 cells inhibited
procasapse-8 processing at the TRAIL-R2 DISC thereby
reducing the levels of fully processed p18-caspase-8
detected in the unbound fraction (Fig. 3e). This indicates
that FLIP(L) facilitates procaspase-8 processing in this
setting and is consistent with the impact of MLN4924
treatment and Cullin-1 silencing, both of which enhance
FLIP(L) and p43-FLIP(L) levels at the TRAIL-R2 DISC
and promote TRAIL-induced apoptosis. Furthermore,
although Cullin-1 depletion enhanced MLN4924-induced
apoptosis, the extent of sensitization to TRAIL-induced
apoptosis was of a similar magnitude to that induced by
MLN4924 alone and siCul1 alone (Supplementary Fig. 3e),
consistent with the primary impact of MLN4924 on TRAIL
sensitivity being mediated by its inhibitory effects on
Cullin-1.
The SCFSkp2 complex interacts with FLIP(L)
We next assessed whether any of the core DISC compo-
nents interact with components of the SCFSkp2 complex. In
Co-IP experiments, we found that Cullin-1 interacts with
FLIP(L) and TRAF2, but not FLIP(S), caspase-8 or FADD
(Fig. 4a and Supplementary Fig. 4a). Endogenous Skp1 and
Skp2 were also detected in these pull-downs; moreover,
exogenous Skp2 was pulled down with FLIP(L), but not
FLIP(S) (Supplementary Fig. 4b). Mapping studies loca-
lised the site of interaction between FLIP(L) and Cullin-1/
Skp2 to a region between amino acids 211 and 350, which
corresponds primarily to the large p20-subunit of its
pseudo-caspase domain (Supplementary Fig. 4c–e). This is
consistent with lack of interaction with FLIP(S), which does
not contain this domain. Further mapping narrowed the
interaction site to a region between amino acids 255 and
292 (Supplementary Fig. 5a–c). In these experiments, it was
noticeable that the interaction between FLIP(L) and Cullin-
1/Skp2 was significantly enhanced by deletion of the C-
terminal region of FLIP(L), which contains the p12-subunit
that is cleaved in a caspase-8-dependent manner at the
DISC. Indeed, p43-FLIP(L)’s (p43) interaction with
SCFSkp2 was significantly stronger than that of unprocessed
FLIP(L) (Fig. 4a and Supplementary Fig. 4d, e). These
results suggested that cleavage of FLIP(L) to its p43-form
promotes its interaction with the SCFSkp2 complex.
We were subsequently able to fine map the SCFSkp2
interaction domain to amino acids 255-267 in FLIP(L)
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(Fig. 4b, c). Moreover, a Biotin-tagged peptide corre-
sponding to this 13 amino acid region (plus additional
flanking residues) interacted with all SCFSkp2 components
in pull-down studies (Fig. 4d). Using a model of the large
and small catalytic subunits of the caspase-8/FLIP(L) het-
erodimer derived from its crystal structure [29], we found
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that much of the 13 amino acid SCFSkp2 interaction region
(red) in the p20-subunit of FLIP(L) is present on the protein
surface and therefore available for forming protein–protein
interactions, although some amino acids are buried in the
interface with the p12-subunit (Fig. 4e–g). FLIP(L) is
cleaved between its large (p20) and small (p12) catalytic
subunits by caspase-8 to generate p43-FLIP(L) when it
forms a heterodimer with caspase-8 at the DISC and related
complexes; cleavage between these domains by caspase-8 at
the DISC may enhance the surface exposure of the SCFSkp2
binding domain explaining the observed enhanced interac-
tion between SCFSkp2 and p43-FLIP(L). This 13 amino acid
region in FLIP(L) is not conserved in procaspase-8, which
has a 21 amino acid insertion in this region (Fig. 4f, g and
Supplementary Fig. 5d), consistent with the lack of inter-
action between SCFSkp2 and caspase-8 (Fig. 4a).
FLIP(L) cleavage promotes its degradation
Given the proximity of FLIP(L)’s SCFSkp2 interaction site to
its p12-domain, we further investigated the effect of FLIP
(L)’s cleavage for its interaction with SCFSkp2 by generating a
non-cleavable form of FLIP(L) (NC-FLIP(L), D376A).
Again, p43-FLIP(L) interacted more strongly with compo-
nents of the SCFSkp2 complex than the wild-type protein,
whereas the NC-FLIP(L) interacted to the same extent as
wild-type (Fig. 5a). In addition, NC-FLIP(L) was significantly
more stable than FLIP(L) and p43-FLIP(L) (Fig. 5b). These
results indicate that not only does cleavage of FLIP(L) to its
p43-form promote its interaction with SCFSkp2, it also pro-
motes its turnover, suggesting a role for SCFSkp2 in regulating
FLIP(L) ubiquitination and degradation via the ubiquitin-
proteasome system (UPS). In support of this, we found that
RNAi-mediated down-regulation of Cullin-1, Skp1 and Rbx1
decreased ubiquitination of endogenous FLIP (Fig. 5c) as did
Skp2 down-regulation (Fig. 5d). Furthermore, simultaneous
over-expression of Cullin-1 and Skp2 enhanced ubiquitination
of endogenous FLIP, which was reversed with MLN4924
treatment (Fig. 5e). Collectively, these results indicate a key
role for the SCFSkp2 complex in regulating ubiquitination and
turnover of FLIP(L).
Cullin-1 competes with TRAF2, caspase-8 and FADD
for binding to p43-FLIP(L)
We further investigated the interplay between TRAF2, FLIP(L)
and components of the SCFSkp2 complex. Mapping studies re-
confirmed the location of the SCFSkp2interaction site within
FLIP(L) and demonstrated that the TRAF2’s interaction site is
located in an adjacent region, between amino acids 211 and
236 of FLIP(L) (Fig. 6a and Supplementary Fig. 5e). TRAF2
co-immunoprecipitated with SCFSkp2 in the presence of p43-
FLIP(L) or FLIP(L) but not FLIP(S), which does not contain
this region, nor does caspase-8 or FADD (Fig. 4a), even though
TRAF2 has been reported to act as an E3 ligase for caspase-8
at the DISC [25]. In mapping the TRAF2 binding site in FLIP
(L), it was notable that the interaction was stronger once the
Cullin-1 binding region was deleted (Fig. 6a). We subsequently
found that TRAF2’s interaction with Cullin-1 is indirect and
mediated via FLIP(L), as TRAF2 was only pulled down with
Cullin-1 in the presence of p43-FLIP(L) (Fig. 6b). It is also
worth noting that the fraction of p43-FLIP(L) associated with
Cullin-1 (and Skp1, Skp2 and Rbx1) was extensively modified,
potentially by polyubiquitin chains (Fig. 6b). Moreover, neither
caspase-8 nor FADD were detected in this experiment, further
confirming that these proteins do not interact with Cullin-1. In
co-transfection experiments, the interaction of p43-FLIP(L)
with TRAF2, FADD and procaspase-8 was significantly
reduced in cells co-transfected with Cullin-1 (Fig. 6c) and
complementary co-transfection experiments showed that
procaspase-8 disrupted the interaction of p43-FLIP(L) with
Cullin-1 (Fig. 6d and Supplementary Fig. 5f). These results are
indicative of competition between canonical DISC proteins and
SCFSkp2 for binding to p43-FLIP(L). Given the role of FLIP(L)
in promoting procaspase-8 processing at the DISC (Fig. 3e),
this competition between Cullin-1 and caspase-8, FADD and
TRAF2 for binding to p43-FLIP(L) likely explains the
observed Cullin-1-mediated inhibition of TRAIL-induced
apoptosis (Fig. 3b–d) and the ability of MLN4924 to pro-
mote TRAIL-R2-mediated apoptosis (Fig. 1b–d and Supple-
mentary Fig. 1a, b).
Discussion
CRLs account for ~20% of all proteasomal degradation
within the cell [17, 18], and many CRL proteins have been
linked to tumourgenesis [19]. Cullin-3 interacts with the
TRAIL-R2 DISC (which we confirmed) and has been
reported to promote K63-linked ubiquitination of the p10-
Fig. 3 Cullin-1 inhibits TRAIL-induced apoptosis in HCT116 cells.
a Western blot analysis of TRAIL-R2 DISC IP in HCT116 BAX-null
cells transfected for 48 h with 30 nM control (SC) or a pool of Cullin-1
targeted (siCul1) siRNAs prior to treatment with zVAD-fmk (20 µM)
for 2 h and then activation of the TRAIL-R2 receptor for 1 and 3 h.
b Western blot analyses of apoptosis proteins in HCT116 cells
transfected with 10 nM control (SC) or Cullin-1-targeted (siCul1)
siRNAs for 48 h prior to treatment with rTRAIL (10 ng/mL) for 6 h.
High content microscopy analysis of cell death in (c) HCT116 cells
and (d) A549 and HT29 cells transfected with 10 nM control (SC) or
Cullin-1-targeted (siCul1) siRNAs for 24 h prior to treatment with
rTRAIL for an additional 24 h. A student’s T test was performed
between SC and siCul1 samples (Error bars= SEM, ****p < 0.0001,
***p < 0.001, **p < 0.01, *p < 0.05, ns= p > 0.05). e Western blot
analysis of TRAIL-R2 DISC IP in HCT116 BAX-null cells transfected
with 10 nM of a pool of FLIP(L)-specific or a pool of pan-FLIP
siRNAs and treated with 10 µM zVAD-fmk for 16 h prior to DISC
stimulation for 1 h.
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subunit of caspase-8, which enhances its enzymatic activity
and apoptosis induction [21]. NEDDylation is required for
CRLs to be active; however, using the NEDDylation inhibitor
MLN4924, we found that TRAIL-induced apoptosis was
enhanced rather than suppressed in cancer cells co-treated
with MLN4924 and TRAIL, suggesting an alternative
NEDDylation-dependent modulator of TRAIL-R2 apoptotic
signalling. Indeed, we found that Cullin-1 and all the
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components of the SCFSkp2 complex associated with TRAIL-
R2, both in its unstimulated (PLAC) and ligand-stimulated
(DISC) forms.
Cullin-1 was predominantly detected in its NEDDylated
(active) form at the TRAIL-R2 DISC, and inhibition or
depletion of Cullin-1 increased p43-FLIP(L) levels at the
DISC. By forming an enzymatically active heterodimer with
p43/41-caspase-8, p43-FLIP(L) can inhibit apoptosis when
present at high levels at the DISC or promote apoptosis when
present at low levels [30]. In HCT116 cells, down-regulation
of FLIP(L) inhibited procaspase-8 processing at the TRAIL-
R2 DISC indicative of a pro-apoptotic role for FLIP(L) at the
DISC in these cells under these conditions. Consistent with
this, inhibition or down-regulation of Cullin-1 enhanced
TRAIL-induced apoptosis in HCT116 cells and in A549 and
HT29 cells, in which Cullin-1 was also detected at the
TRAIL-R2 DISC; this suggests that by stabilising p43-FLIP
(L) at the DISC, loss of Cullin-1 promotes p43-FLIP(L)-
mediated processing of procaspase-8 and apoptosis induction.
FLIP is frequently over-expressed in cancer and is an
important mediator of chemo- and radio-resistance as well as
apoptosis induced by immune effector cells and therapeutic
agonists [31–34]. The turnover of FLIP is regulated by the
UPS, with half-lives of ~45min for FLIP(S) and ~3 h for
FLIP(L), indicative of distinct regulatory mechanisms for
each [35]. A cytoplasmic complex termed the “FADDosome”
formed in response to the antimetabolite 5-Fluorouracil was
recently described containing FLIP, p53, ATR, caspase-10
and TRAF2, in which TRAF2 ubiquitinates FLIP(L) causing
its degradation and activation of caspase-8-dependent apop-
tosis [36]. ER stress leading to JNK-mediated activation of
ITCH has been reported to lead to ubiquitination and degra-
dation of FLIP(L) [37, 38]. Having identified SCFSkp2 at the
DISC, we explored its interaction with core DISC compo-
nents and identified a specific interaction with FLIP(L), but
not FLIP(S), caspase-8 or FADD. Moreover, down-regulation
of SCFSkp2 components with siRNA decreased FLIP(L) ubi-
quitination, while over-expression of Cullin-1 and Skp2
increased FLIP(L) ubiquitination in a NEDDylation-
dependent manner, providing the first evidence that FLIP(L)
is regulated by the SCFSkp2 complex.
Mapping experiments revealed that SCFSkp2 interacted
with amino acids 255-267 within the p20 pseudo-catalytic
domain of FLIP(L), a region not present in FLIP(S), nor
caspase-8. Importantly, a stronger interaction with SCFSkp2
was detected with p43-FLIP(L), which is generated by
caspase-8 in FADD-dependent complexes such as the DISC.
Molecular modelling of the FLIP(L):procaspase-8 hetero-
dimer indicated that the Cullin-1 binding site in FLIP(L)’s
p20-subunit is partly buried in the interface with its p12-
subunit, suggesting that cleavage between these domains by
caspase-8 at the DISC may enhance the surface exposure of
the SCFSkp2 binding domain. Thus, our data suggest a model
in which processing of FLIP(L) to p43-FLIP(L) at the
TRAIL-R2 DISC enhances its interaction with co-localised
SCFSkp2, leading to targeting of p43-FLIP(L) to the protea-
some and reduced levels of the FLIP(L):caspase-8 hetero-
dimer (Fig. 6e). This is consistent with the longer half-life of
non-cleavable FLIP(L) and Cullin-1’s ability to disrupt p43-
FLIP(L)’s interactions with FADD/caspase-8, indicative of
competition between the SCFSkp2 complex and canonical
DISC proteins for p43-FLIP(L) binding. Thus, in the absence
of Cullin-1, enhanced levels of the p43-FLIP(L):caspase-8
heterodimeric enzyme at the TRAIL-R2 DISC would pro-
mote processing of its local substrates, including proximal
procaspase-8 homodimers, thereby facilitating full processing
of procaspase-8 to its fully active heterotetrameric form,
leading to the enhanced levels of apoptosis that we observed
in Cullin-1-depleted/inhibited cells.
FLIP(L)’s TRAF2 binding site, which we mapped to the
linker region between DED2 and its p20-subunit, is adjacent to
the Cullin-1 binding site, and the binding of TRAF2 to p43-
FLIP(L) is clearly weakened by Cullin-1, suggesting compe-
tition between the SCFSkp2 complex and TRAF2 for binding to
DISC-processed FLIP(L). Thus, in cells treated with MLN4924
or siCullin-1, DISC recruitment of TRAF2 was enhanced along
with FLIP(L). Our findings agree with those of others [39, 40]
that TRAF2 forms part of a FADD- and caspase-8-independent
TRAIL-R2 PLAC and suggest that like other E3 ligases, c-Cbl/
Cbl-b and A20, SCFSkp2 can also associate with this complex.
Moreover, our findings agree with earlier studies which
reported that TRAF2 interacts with p43-FLIP(L) at the DISC,
leading to the latter’s stabilisation [41].
In conclusion, we report that SCFSkp2 can interact with
TRAIL-R2 and regulate the turnover of FLIP(L) and its
interactions with core DISC components. Whereas Cullin-3
Fig. 4 Mapping the SCFSkp2 interaction site within FLIP(L). a Co-
IP analysis of the interaction of Cullin-1 with full-length FLIP(L), p43-
FLIP(L) (p43), FLIP(S), procaspase-8 (Casp8) and FADD; interactions
with endogenous Skp1, Skp2 and TRAF2 were also assessed.
b Schematic diagram of FLIP expression constructs; the death effector
domains (DEDs) and large (p20) and small (p12) subunits of the
pseudo-caspase domain are highlighted. The red box indicates the
region important for SCFSkp2 interaction, as deduced from Co-IP
experiment mapping the interaction site between FLIP(L) and Cullin-1
and (c) Skp2. d Biotinylated peptide of FLIP(L)’s SCFSkp2 interaction
site pull-down experiment demonstrating the interaction of this region
with the SCFSkp2 complex. e Space-filling and ribbon models of the
Cullin-1 interaction site in the large p20-subunit of FLIP(L) and its
spatial orientation with respect to the p12 small subunit. f Ribbon
models of the Cullin-1 interaction site in FLIP(L) and the corre-
sponding region of caspase-8. g Model derived from the crystal
structure (PDB ID: 3H11) of the large and small catalytic domains of
the caspase-8/FLIP(L) heterodimer. The position of the SCFSkp2
complex interaction site and the equivalent (non-contiguous) residues
in caspase-8 are highlighted in red. A frontal view of the heterodimer
interface is depicted in the middle; the “windows” show 90° rotations
of the crystal structure, highlighting the SCFSkp2 interaction of FLIP(L)
and its equivalent region in Procaspase-8.
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regulates the TRAIL-R2 DISC by modulating caspase-8,
our results indicate that Cullin-1 regulates the DISC pri-
marily by modulating FLIP(L). Thus, our findings add to
our understanding of how TRAIL-R2 signalling and FLIP
are controlled with implications for therapeutically mod-
ulating this pathway.
Methods
Cell culture
HCT116 cells were cultured in McCoy’s 5 A Modified
Medium, supplemented with 10% foetal calf serum (FCS) and
Fig. 5 FLIP(L) cleavage promotes its interaction with SCFSkp2.
a Co-IP analysis of the interaction of Cullin-1 with wild-type, non-
cleavable (NC)-FLIP(L) and p43-FLIP(L). Interactions with endo-
genous Skp1, Skp2 and TRAF2 were also assessed. b Western blot
assessment of degradation rates of wild-type-, NC- and p43-FLIP(L)
using 100ug/mL cycloheximide (CHX). c Western blot of FLIP
ubiquitination in HCT116 cells transfected for 48 h with siRNAs
(20 nM) targeting Rbx1, Skp1 or Cullin-1. d Western blot analysis of
FLIP ubiquitination in HCT116 cells transfected for 48 h with siRNAs
(10 nM) targeting Skp2. g Impact of Cullin-1 and Skp2 over-
expression on FLIP ubiquitination in the presence/absence of
MLN4924 (300 nM, 3 h).
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2mM L-glutamine (all from Life Technologies).
HEK293T cells were maintained in Dulbecco’s Modified
Eagle Medium (DMEM), supplemented with 10% foetal calf
serum (FCS) and 1mM Sodium Pyruvate (all from Life
Technologies). COLO205 cells were maintained in Roswell
Park Memorial Institute (RPMI) 1640 Medium (Sigma
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Aldrich, Gillingham, Dorset, UK), supplemented with 10%
FCS (Life Technologies). A549, RKO, HT29 and LIM1215
cells were maintained in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% FCS (all from Life Tech-
nologies). HAP1 cells were maintained in Iscove’s Modified
Dulbecco’s Medium (IMDM), supplemented with 10% foetal
calf serum (all from Life Technologies). Cells were main-
tained in a tissue culture incubator (Sanyo Europe, Herts, UK)
at 5% CO2 and 37 °C. HCT116, HCT116 BAX null, HCT116
p53 null, HT29, RKO, LIM1215, COLO205, A549 and
HEK293T cells were obtained from American Type Culture
Collection (ATCC, Manassas, VA, USA). HAP1 cells were
obtained from Horizon Discovery (Cambridge, UK). Imme-
diately after purchase, early passage stocks of each cell line
were frozen down. After thawing, cells were kept for a limited
number of passages and were regularly screened for the
presence of mycoplasma using the MycoAlert Mycoplasma
Detection Kit (Lonza, Basel, Switzerland).
Oligonucleotide transfections
A 3:1 ratio of FuGENE® HD Transfection Reagent (Pro-
mega) (µL) to plasmid DNA (µg) was used for transfections.
In 100 µL of OptiMEM (Life Technologies), FuGENE then
plasmid DNA was added and left to incubate for 15 min at
room temperature. The mixture was then added to cells in
culture and was left for 24–48 h. For siRNA transfections,
siRNA and Lipofectamine® RNAiMAX (Invitrogen) were
added separately to OptiMEM (Life Technologies) before
being mixed together and left to incubate at room tem-
perature for 15 min. Culture medium was then added to the
mixture, to allow total cell coverage, and was used to
replace the medium on cells, which was then left to incubate
at 5% CO2, 37 °C for 4 h. Further culture medium was then
added, to normal culturing levels, and then cells were left
for the indicated times.
Immunoblotting
Cell lysates were prepared or immunoprecipitation (IP)
samples were eluted using Loading buffer, subsequently
followed by heating at 95 °C for 5 min. SDS-PAGE was
then implemented to separate proteins by molecular weight
using the Mini-PROTEAN 3 electrophoresis module appa-
ratus (Bio-rad). The gels were then subsequently transferred
using the Pierce Power Blotter (Thermo Scientific), with
reagents and instructions used from the Trans-Blot®
Turbo™ RTA Mini Nitrocellulose Transfer Kit (Bio-rad),
for 11 min, at a constant of 25 V. Membranes were then
incubated with the appropriate Primary antibody overnight
at 4 °C and then a minimum of 3 h at 4 °C with the
appropriate Secondary antibody. Protein expression was
analysed and detected using the Western Lightning® Plus-
ECL, Enhanced Chemiluminescence Substrate (Perki-
nElmer) and G:BOX Chemi XX6 gel doc system (Syn-
gene). A list of antibodies is provided as a Supplementary
Table.
Ubiquitination assay
Cells grown in a P90 plate, typically collected at over 80%
confluency, were washed once in ice-cold PBS to stop
dynamic ubiquitination events from occurring; all proce-
dures were then conducted at 4 °C for the same reason.
Cells were transferred to tubes and were pelleted by cen-
trifugation at 2400 rpm for 5 min; supernatant was subse-
quently removed. Cells were then lysed with 250 µL of
SDS-free RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl,
5 mM EDTA, 1% Triton X-100, dH2O), supplemented
with an EDTA free protease inhibitor cocktail, for 20 min
before centrifugation at 13,00 rpm for 5 min, followed by
the supernatant being transferred to fresh tubes. 25 µL of
10% SDS was added (Final concentration 1%) and the
sample was heated at 95 °C for 5 min; to facilitate dena-
turation of the samples. The samples were then diluted
with 750 µL of SDS-free RIPA buffer, supplemented with
an EDTA free protease inhibitor cocktail, to dilute the SDS
and allow the immunoprecipitation (IP) antibody to func-
tion efficiently; samples were then incubated with 1 µL of
either FLIP (H-202) antibody (Santa Cruz biotechnology)
or FLAG (M2) antibody (Sigma) overnight at 4 °C while
rotating. Thirty microliters of the appropriate washed
Dynabeads™ M-280 (Invitrogen) were then added to the
samples and left to incubate for 6 h at 4 °C while rotating.
The beads were then washed 5 times in SDS-free RIPA
buffer and eluted in Loading buffer before being heated at
95 °C for 5 min.
Fig. 6 Cullin-1 competes with TRAF2, caspase-8 and FADD for
binding to p43-FLIP(L). a Co-IP analysis of the interaction of Cullin-1
with full-length and truncated forms of FLIP(L); interactions with endo-
genous Skp1, Skp2 and TRAF2 were also assessed. b Co-IP analysis of
the interaction of p43-FLIP(L) with Cullin-1 and endogenous Rbx1, Skp1
and Skp2. Components of the DISC were also assessed; neither caspase-8
nor FADD were detected, however TRAF2 was detectable, but only in
cells co-transfected with p43-FLIP(L). c Co-IP analysis of the interaction
of p43-FLIP(L) with endogenous FADD, caspase-8 and TRAF2 in the
presence and absence of over-expressed Cullin-1; endogenous Skp1 and
Skp2 were also assessed. d Co-IP analysis of the interaction of Myc-
tagged Cullin-1 and endogenous Skp2 with FLAG-tagged p43-FLIP(L) in
cells co-transfected with increasing amounts of FLAG-tagged procaspase-
8 (C8). e Schematic summary: cleavage of FLIP(L) to p43-FLIP(L) at the
TRAIL-R2 DISC (by proximal FLIP(L)/caspase-8 heterodimers or
caspase-8 homodimers) enhances its interaction with Cullin-1, which
disrupts its interaction with caspase-8, FADD and TRAF2 and promotes
its ubiquitination and proteasomal degradation by SCFSkp2. This is facili-
tated by the constitutive interaction of SCFSkp2 with TRAIL-R2 and
reduces the levels of the FLIP(L):caspase-8 heterodimeric enzyme at the
DISC, thereby modulating TRAIL-induced caspase-8 activation and
apoptosis induction.
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Co-Immunoprecipitation (Co-IP)
Cells grown in a P90 plate, typically collected at over 80%
confluency, were washed once in ice-cold PBS to stop
disruption of protein:protein interactions; all procedures
were then conducted at 4 °C for the same reason. One
milliliter of SDS-free RIPA buffer (50 mM Tris pH 7.4,
150 mM NaCl, 5 mM EDTA, 1% Triton X-100, dH2O),
supplemented with an EDTA free protease inhibitor cock-
tail, was added onto cells within the plate and was left
shaking for 20 min. Cell lysates were then transferred to a
tube, centrifuged at 13,000 rpm for 5 min and the super-
natant was transferred to a fresh tube. Either 1 µL of FLIP
(H-202) antibody (Santa Cruz biotechnology)/Myc-Tag
(9B11) antibody (Cell Signalling Technology) or 20 µL of
FLAG (M2) Magnetic Beads (Sigma) were added to the cell
lysates and were left to rotate overnight at 4 °C. The fol-
lowing day 15 µL of the appropriate washed Dynabeads™
M-280 (Invitrogen) were added to the samples and were left
to rotate for a further 6 h. The beads were then washed 5
times with SDS-Free RIPA buffer and were eluted in
Loading buffer, followed by heating at 95 °C for 5 min.
However, if the FLAG (M2) Magnetic Beads were used the
Dynabeads step was skipped and beads were washed
straight away.
TRAIL-R2 DISC IP
A total of 1.2 mg of anti-TRAIL-R2/DR5 antibody
(Conatumumab, AMG655) (Amgen Inc.) was covalently
attached to 6 mg of Dynabeads in a volume of 6 mL using
the Dynabead® Antibody Coupling Kit (Life Technolo-
gies), according to the manufactory’s instructions.
Typically, a P90 plate containing 10 mL of growth
medium was inoculated with 30 µL of anti-DR5 beads
when cells were approximately 60% confluent. The cells
were then washed once in ice-cold PBS to slow down
DISC dynamics and further procedures were carried out
at 4 °C for the same reason. One milliliter of DISC IP
buffer (20 mM Tris 7.4, 150 mM NaCl, 0.2% NP-40,
10% Glycerol, dH2O), supplemented with an EDTA free
protease inhibitor cocktail, was added onto cells within
the plate and allowed to shake for 60 min, then was
transferred to a fresh tube. Anti-DR5 beads were isolated
magnetically and washed 5 times with DISC IP buffer;
the first flow-through was collected and termed the
‘Unbound Fraction’. Beads were then eluted using
Loading buffer and analysed by Immunoblotting.
AMG655 is an agonist antibody for TRAIL-R2DR5,
therefore, activating the receptor, when it is immuno-
precipitated after being added to live cells any complexes
that associate with active DR5 (like the DISC) are also
immunoprecipitated as well.
Biotin pull down
For each sample, 25 µL of Dynabeads™ MyOne™ Strep-
tavidin T1 (Invitrogen) were first washed in SDS-free RIPA
buffer (50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA,
1% Triton X-100, dH2O) and then resuspended in SDS-Free
RIPA+ 2% BSA for blocking. 20 µg of the Biotin-tagged
peptide (peptides&elephants) was then conjugated to the
beads at room temperature of 30 min while rotating. The
conjugated beads were then washed with SDS-Free RIPA
buffer and incubated with 50 µg of cell lysate, collected in
SDS-Free RIPA buffer supplemented with an EDTA free
protease inhibitor cocktail, for 4 h at 4 °C while rotating.
Beads were then washed with SDS-Free RIPA buffer and
eluted in Loading buffer, followed by heating at 95 °C for
5 min. Samples were then analysed by immunoblotting.
Site-directed mutagenesis
Site-directed mutagenesis was carried out using the KOD
Xtreme™ Hot Start DNA Polymerase kit (Merck). Briefly,
a PCR reaction (100 µL scale) incorporating 50 µL 2x
buffer, 20 µL of 2 mM dNTPs, 6 µL each of 5 µM forward
and reverse primers (containing the desired mutations), 16
µL of 10 ng/µL template DNA and 2 µL KOD polymerase
were set up, according to the manufacturer’s instructions.
Fifty microliters of the completed PCR reaction mixture
was then digested with 2.5 µL Dpn1 and 5.8 µL CutSmart®
Buffer (New England Biolabs) for 3 h at 37 °C to degrade
methylated template DNA. CaCL2 competent DH5α bac-
teria were then transformed with the digested PCR mixture
and plated onto agar with the appropriate selection marker.
Subsequent colonies were then expanded, and clonal DNA
was isolated using the QIAprep Spin Miniprep Kit (QIA-
GEN). Mutations in DNA were then verified by DNA
sequencing (GATC BIOTECH).
Caspase activity assay
Twenty-five microliters of Caspase-Glo®-3/7 or -8 reagent
(Promega) was added to 5 µg (Caspase-3/7 activity) or
10 µg (Caspase-8 activity) of cell lysate, made up to 25 µL
with PBS in a white-walled 96-well plate in duplicate. The
plate was incubated in the dark at room temperature for
45 min and subsequently read at 1 s integrated reads in a
luminescent plate reader (Biotek Synergy 4 plate reader).
All conditions were performed in duplicate.
High content fluorescent microscopy
This method was used to assess apoptotic cell death. Cells
were seeded into a 96-well glass-bottom plate (Cellvis) and
left to adhere overnight. After treatments, cells were
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incubated with 10x Annexin V Binding Buffer (made to 1×)
(BD Pharmingen), 1:1000 FITC Annexin V (BD Pharmin-
gen), 0.333 µg/mL Propidium Iodide (Sigma Aldrich) and
1.33 µg/mL Hoechst 33342 (Thermo Fisher Scientific) for
20min at 37 °C. Images were then taken on the ArrayScan™
XTI HCA Reader, integrated with the CrEST™ X-Light™
Confocal Scan Head (Thermo Fisher Scientific) and the HCS
Studio Cell Analysis Software V6.6.0 (Thermo Fisher Sci-
entific) was used to analyse the images. Briefly, the software
would recognise a cell as an object that was stained with
Hoechst (blue), which stains all cells’ nuclei. Once the
software had determined the cell as a valid object, it would
detect whether the cell was also stained with Annexin V
(AV:green), an indicator of early and late apoptosis, or
Propidium Iodide (PI:red), an indicator of non-viable cells
(Example images are in Supplementary Fig. 1a). The
ArrayScan™ XTI HCA Reader would take multiple images
from within a well until it had reached a target of 2,000 cells,
or the maximum numbers of images had been taken for the
given well. While images were being taken, the software
would calculate the percentage of stained cells (either AV or
PI or both), indicating total death, and this was plotted on a
graph. All conditions were performed in triplicate.
Sub-cellular fractionation
The ProteoExtract® Subcellular Proteome Extraction Kit
(Calbiochem) was used to generate lysates from the cyto-
solic, nuclear and cytoskeletal/lipid raft fractions of the cell,
according to the manufacturer’s instructions. The fractions
were then subsequently analysed by immunoblotting.
Protein half-life
Protein expression was analysed by Immunoblotting and
quantified by densitometry, using ImageJ (NIH), normal-
ising to the loading control. Treatment values were con-
verted into ratios of its 0 h timepoint (given the value (1)
and were plotted. GraphPad Prism 8 was then used to
generate a decay curve for treatments, by using the one-
phase exponential decay equation.
Statistical analysis
Statistical significance was calculated from distinct techni-
cal replicates (n ≥ 3), either by student’s T test (two-tailed,
two sample equal variance on unpaired data) or two-way
ANOVA in GraphPad Prism 8. Graphs were plotted as
means with error bars represented as SEM; statistical sig-
nificance was denoted as follows: ****p < 0.0001, ***p <
0.001, **p < 0.01, *p < 0.05, ns= p > 0.05. Experimental
phenotypes were confirmed in at least three independent
experiments.
Data availability
The data supporting the findings of the study are available
from the corresponding author on reasonable request.
Acknowledgements This work was funded by grants from The
Wellcome Trust (110371/Z/15/Z), Cancer Research UK (C11884/
A24387), Northern Ireland Department for the Economy (NI DfE)
(SFI-DEL 14/1 A/2582) and a NI DfE studentship (JZR). We thank
Prof Henning Walczak (UCL Cancer Institute) for supplying the IZ-
TRAIL expression construct, Dr Jon Vosper (Innsbruck Medical
University) for supplying the FLAG-tagged Skp2 expression construct
and its corresponding truncation, and Prof Markus Rehm (Stuttgart)
for supplying the TRAIL-R2/DR5 knockout HCT116 cell line.
Author contributions JZR: conceptualization, methodology, valida-
tion, formal analysis, investigation, writing (original draft) and
visualization; CH: conceptualization, methodology, validation, formal
analysis and investigation; TS: investigation and visualization; JF:
investigation; NC: methodology, investigation and supervision; JSR:
investigation; HK: investigation; JM: resources and supervision; EE:
methodology and investigation; LMH: investigation; J. Ferris: inves-
tigation; C. Higgins: methodology and investigation; G-EF: investi-
gation; PM: funding acquisition and writing (review and editing);
SSM: funding acquisition and writing (review and editing); DBL:
conceptualization, methodology, validation, formal analysis, writing
(original draft), visualization, supervision, project administration and
funding acquisition.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Vaux DL, Korsmeyer SJ. Cell death in development. Cell Cell
Press. 1999;96:245–54. https://www.sciencedirect.com/science/a
rticle/pii/S0092867400805644?via%3Dihub.
2. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demoli-
tion at the cellular level. Nat Rev Mol Cell Biol. 2008;9:231–41.
http://www.ncbi.nlm.nih.gov/pubmed/18073771.
3. Humphreys L, Espona-Fiedler M, Longley DB. FLIP as a ther-
apeutic target in cancer. FEBS J. 2018. http://www.ncbi.nlm.nih.
gov/pubmed/29806737.
2740 J. Z. Roberts et al.
4. Riley JS, Malik A, Holohan C, Longley DB. DED or alive:
assembly and regulation of the death effector domain complexes.
Cell Death Dis. 2015;6:e1866 http://www.nature.com/doifinder/
10.1038/cddis.2015.213.
5. Keller N, Mareš J, Zerbe O, Grütter MG. Structural and bio-
chemical studies on procaspase-8: new insights on initiator cas-
pase activation. Structure. 2009;17:438–48. http://www.ncbi.nlm.
nih.gov/pubmed/19278658.
6. McLornan DP, et al. Prognostic significance of TRAIL signaling
molecules in stage II and III colorectal cancer. Clin Cancer Res.
2010;16:3442–51. http://www.ncbi.nlm.nih.gov/pubmed/20570920.
7. McCarthy MM, et al. Evaluating the expression and prognostic
value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer
Res. 2005;11:5188–94.
8. Spierings DCJ, et al. Expression of TRAIL and TRAIL death
receptors in stage III non-small cell lung cancer tumors. Clin
Cancer Res. 2003;9:3397–405.
9. Leverkus M, et al. Regulation of tumor necrosis factor-related
apoptosis-inducing ligand sensitivity in primary and transformed
human keratinocytes. Cancer Res. 2000;60:553–9. http://www.
ncbi.nlm.nih.gov/pubmed/10676636.
10. Walczak H, et al. Tumoricidal activity of tumor necrosis factor-
related apoptosis-inducing ligand in vivo. Nat Med.
1999;5:157–63. http://www.nature.com/articles/nm0299_157.
11. Tolcher AW, et al. Phase I pharmacokinetic and biologic
correlative study of mapatumumab, a fully human monoclonal
antibody with agonist activity to tumor necrosis factor-related
apoptosis-inducing ligand receptor-1. J Clin Oncol.
2007;25:1390–5.
12. Plummer R, et al. Phase 1 and pharmacokinetic study of lex-
atumumab in patients with advanced cancers. Clin Cancer Res.
2007;13:6187–94.
13. Kumar S, Yoshida Y, Noda M. Cloning of a cDNA which encodes a
novel ubiquitin-like protein. Biochem Biophys Res Commun.
1993;195:393–9. http://www.ncbi.nlm.nih.gov/pubmed/8395831.
14. Kumar S, Tomooka Y, Noda M. Identification of a set of genes
with developmentally down-regulated expression in the mouse
brain. Biochem Biophys Res Commun. 1992;185:1155–61.
http://www.ncbi.nlm.nih.gov/pubmed/1378265.
15. Hori T, et al. Covalent modification of all members of human cullin
family proteins by NEDD8. Oncogene. 1999;18:6829–34.
http://www.ncbi.nlm.nih.gov/pubmed/10597293.
16. Jones et al. A targeted proteomic analysis of the ubiquitin-like
modifier nedd8 and associated proteins. J Proteome Res.
2018;7:1274–87. http://www.ncbi.nlm.nih.gov/pubmed/18247557.
17. Soucy TA, et al. An inhibitor of NEDD8-activating enzyme as a
new approach to treat cancer. Nat. 2009;458:732–73. http://www.
nature.com/doifinder/10.1038/nature07884.
18. Petroski MD, Deshaies RJ. Function and regulation of cullin-
RING ubiquitin ligases. Nat Rev Mol Cell Biol. 2005;6:9–20.
http://www.ncbi.nlm.nih.gov/pubmed/15688063.
19. Wang Z, Liu P, Inuzuka H, Wei W. Roles of F-box proteins in
cancer. Nat Rev Cancer. 2014;14:233–47. http://www.nature.com/
doifinder/10.1038/nrc3700.
20. Lafont E, Hartwig T, Walczak H. Paving TRAIL’s path with
ubiquitin. Trends Biochem Sci. 2017;43:44–60. Available from
https://doi.org/10.1016/j.tibs.2017.11.002.
21. Jin Z, et al. Cullin3-based polyubiquitination and p62-dependent
aggregation of caspase-8 mediate extrinsic apoptosis signaling.
Cell. 2009;137:721–35.
22. Brownell JE, et al. Substrate-assisted inhibition of ubiquitin-
like protein-activating enzymes: the NEDD8 E1 inhibitor
MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell
2010;37:102–11.
23. Wilson TR, et al. Combined inhibition of FLIP and XIAP
induces Bax-independent apoptosis in type II colorectal cancer
cells. Oncogene. 2009;28:63–72. http://www.nature.com/articles/
onc2008366.
24. Majkut J, et al. Differential affinity of FLIP and procaspase
8 for FADD’s DED binding surfaces regulates DISC assembly.
Nat Commun. 2014;5:3350. http://www.nature.com/articles/
ncomms4350.
25. Gonzalvez F, et al. TRAF2 sets a threshold for extrinsic apoptosis
by tagging caspase-8 with a Ubiquitin shutoff timer. Mol Cell.
2012;48:888–99.
26. Schuler S, et al. SKP2 confers resistance of pancreatic cancer cells
towards TRAIL-induced apoptosis. Int J Oncol. 2011;38:219–25.
http://www.spandidos-publications.com/ijo/38/1/219.
27. Hughes MA, et al. Co-operative and hierarchical binding of c-
FLIP and caspase-8: a unified model defines how c-FLIP isoforms
differentially control cell fate. Mol Cell. 2016;61:834–49.
28. Henry CM, Martin SJ. Caspase-8 acts in a non-enzymatic role
as a scaffold for assembly of a pro-inflammatory “FADDosome”
complex upon TRAIL stimulation. Mol Cell. 2017;65:715–29.e5.
29. Yu JW, Jeffrey PD, Shi Y. Mechanism of procaspase-8 activation
by c-FLIPL. Proc Natl Acad Sci USA. 2009;106:8169–74.
30. Humphreys LM, et al. A revised model of TRAIL ‐R2 DISC
assembly explains how FLIP (L) can inhibit or promote apoptosis.
EMBO Rep. 2020;21:e49254. https://doi.org/10.15252/embr.
201949254.
31. Carson R, et al. HDAC inhibition overcomes acute resistance to
MEK inhibition in BRAF-mutant colorectal cancer by down-
regulation of c-FLIPL. Clin Cancer Res. 2015;21:3230–40.
http://www.ncbi.nlm.nih.gov/pubmed/25813020.
32. Crawford N, et al. SAHA overcomes FLIP-mediated inhibition of
SMAC mimetic-induced apoptosis in mesothelioma. Cell Death
Dis. 2013;4:e733. http://www.nature.com/articles/cddis2013258.
33. Paul I, et al. Acquired differential regulation of caspase-8 in
cisplatin-resistant non-small-cell lung cancer. Cell Death Dis.
2012;3:e449. http://www.nature.com/articles/cddis2012186.
34. McLaughlin KA, et al. FLIP: a targetable mediator of resistance to
radiation in non-small cell lung cancer. Mol Cancer Ther.
2016;15:2432–41. http://www.ncbi.nlm.nih.gov/pubmed/27474150.
35. Poukkula M, et al. Rapid turnover of c-FLIPshort is determined by
its unique C-terminal tail. J Biol Chem. 2005;280:27345–55.
http://www.ncbi.nlm.nih.gov/pubmed/15886205.
36. Mohr A, et al. Caspase-10: a molecular switch from cell-
autonomous apoptosis to communal cell death in response to
chemotherapeutic drug treatment. Cell Death Differ.
2018;25:340–52.
37. Chang L, et al. The E3 ubiquitin ligase itch couples JNK activa-
tion to TNFα-induced cell death by inducing c-FLIPL turnover.
Cell. 2006;124:601–13.
38. Santini S, et al. ATM kinase activity modulates ITCH E3-
ubiquitin ligase activity. Oncogene. 2014;33:1113–23.
39. Bellail AC, Olson JJ, Yang X, Chen ZJ, Hao C. A20 ubiquitin
ligase-mediated polyubiquitination of RIP1 inhibits caspase-8
cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer
Discov. 2012;2:140–55. http://www.ncbi.nlm.nih.gov/pubmed/
22585859.
40. Xu L, et al. DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-
induced apoptosis by promoting TRAF2-mediated polyubiquitina-
tion of caspase-8 in gastric cancer cells. Mol Oncol.
2017;11:1733–51. http://www.ncbi.nlm.nih.gov/pubmed/28972304.
41. Tschopp J, Kataoka T. N-terminal fragment of c-FLIP(L) pro-
cessed by caspase 8 specifically Interacts with TRAF2 and induces
activation of the NF-kB signaling pathway. Mol Cell Biol.
2004;24:2627–36.
The SCFSkp2 ubiquitin ligase complex modulates TRAIL-R2-induced apoptosis by. . . 2741
